LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Inc.

In a report released on May 8, Rick Wise from Stifel Nicolaus maintained a Buy rating on Lemaitre Vascular, with a price target of $120.00. The com...

Lemaitre Vascular (LMAT) Gets a Buy from Stifel Nicolaus

In a report released today, James Sidoti from Sidoti maintained a Buy rating on Lemaitre Vascular, with a price target of $132.00. According to Tip...

Lemaitre Vascular (LMAT) Receives a Buy from Sidoti

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)...

Current Quarter	$0.81	Next Quarter	$0.72
Current Year	$3	Next Year	$3.27
QoQ Growth	-11.1%	YoY Growth	+9.0%
3Y EPS CAGR	+39.5%	Target Price	$116.86
Consensus	Buy	Upside	+18.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LMAT	$98.71	+0.98%	430.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LMAT	$98.71	+1.0%	430.12K
3
4
5
6

LMAT

LMAT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get LeMaitre Vascular Inc. Data in Excel

Get LeMaitre Vascular Inc. Data in Excel